Combination therapy response biomarkers of colorectal cancer
Posted in the Colon Cancer Forum
#1 Feb 21, 2012
According to this recent US patent application, high pretreatment plasma YKL-40 and serum YKL-40 levels were prognostic biomarkers of short overall survival in two independent studies of patients with metastatic colorectal cancer treated with third-line cetuximab in combination with irinotecan. Details: http://www.sciclips.com/sciclips/biomarker-ne...
Add your comments below
|Less invasive may be best way (Jan '14)||Apr '14||Deb||5|
|City of Toronto refuses to pay for funeral of u... (Jan '14)||Jan '14||wild child||8|
|The 10 commandments of cancer prevention (May '09)||Nov '13||One for all All f...||5|
|FDA approves Amgen colon cancer drug Vectibix (Feb '07)||Nov '13||yoram||2|
|BLOG: Farrah Fawcett's Cancer Battle Raising Qu... (May '09)||Sep '13||bud_schmones||6|
|Antidepressant enhances chemotherapy drug (Dec '08)||Sep '13||Dashawn||2|
|In colon cancer drug study, more wasna t better (Feb '09)||Sep '13||Ezekiel||5|
Find what you want!
Search Colon Cancer Forum Now